ライフサイエンスコーパス: developed country

1 a, with lifestyle and hygiene standards of a developed country.

2 ion and skin prick test reactivity even in a developed country.

3 infectious cause of newborn malformation in developed countries.

4 nd plasma derived, are emerging, at least in developed countries.

5 IE) occurs in 1 to 8 per 1000 live births in developed countries.

6 s have compared the United States with other developed countries.

7 e cancer landscape in Latin America and more developed countries.

8 ntries, and in the Indigenous populations of developed countries.

9 inue to be the primary cause of mortality in developed countries.

10 te on humans and currently resurgent in many developed countries.

11 radic encephalitis and blinding keratitis in developed countries.

12 the condition of low aerosol mass loading in developed countries.

13 e leading cause of irreversible blindness in developed countries.

14 lobally and a substantial economic burden in developed countries.

15 g programs are possible only in economically developed countries.

16 rom sepsis is increasing in the UK and other developed countries.

17 al and population concern in the majority of developed countries.

18 life-threatening disease worldwide, even in developed countries.

19 use of these agents in children with AGE in developed countries.

20 is the leading cause of preventable death in developed countries.

21 (AMD) is the leading cause of vision loss in developed countries.

22 t are different from those typically used in developed countries.

23 ues relevant to reduction of child deaths in developed countries.

24 er damage requiring liver transplantation in developed countries.

25 plantation in some countries rivals those in developed countries.

26 clinical use of probiotics in outpatients in developed countries.

27 ignificant and likely to be similar in other developed countries.

28 ndemic hepatitis E (HE) has been reported in developed countries.

29 ortality has fallen to very low rates in all developed countries.

30 cally in the last few decades in westernized developed countries.

31 out the world, now ranging from 10 to 20% in developed countries.

32 e strategy with currently available drugs in developed countries.

33 g in OS and DFS similar to those reported in developed countries.

34 ature of elevated SES in many populations in developed countries.

35 g 1983 to 2002 predominantly in economically developed countries.

36 iseases for the prevention of vision loss in developed countries.

37 related with antimicrobial resistance within developed countries.

38 n reasons for emergency department visits in developed countries.

39 be different from those in larger cities and developed countries.

40 ith growth faltering seen in infants in less-developed countries.

41 tributed to a plateau in stillbirth rates in developed countries.

42 Stroke is the leading cause of disability in developed countries.

43 most frequently diagnosed cancer in males in developed countries.

44 ion during pregnancy is a common practice in developed countries.

45 patients than that reported for patients in developed countries.

46 oth in the USA and between the USA and other developed countries.

47 % for children treated on clinical trials in developed countries.

48 hepatitis C virus (HCV) transmission in most developed countries.

49 cause of food and waterborne illness in the developed countries.

50 particularly in the United States and other developed countries.

51 y is a major health concern, particularly in developed countries.

52 by accidental gun use than children in other developed countries.

53 ty) and the implications for human health in developed countries.

54 now responsible for 2-3% of children born in developed countries.

55 rom other international studies conducted in developed countries.

56 BS) is a leading cause of neonatal sepsis in developed countries.

57 egnant women and young children (6-24 mo) in developed countries.

58 h uncertain consequences for human health in developed countries.

59 e treated in developing countries and 41% in developed countries.

60 n donation have been one of the lowest among developed countries.

61 oping countries, but different from those in developed countries.

62 s and current mortality rates for nine major developed countries.

63 that it is often recurrent and is common in developed countries.

64 which are the leading cause of mortality in developed countries.

65 d with this modality continues to decline in developed countries.

66 ronic liver disease in the United States and developed countries.

67 tis (NASH) is the commonest liver disease in developed countries.

68 ramming have AE rates comparable to those in developed countries.

69 se of invasive disease in early childhood in developed countries.

70 4.5% in developing countries and by 30.3% in developed countries.

71 e distribution of genotypes observed in most developed countries.

72 ecoming a major economic expenditure for all developed countries.

73 ults and an increasing number of children in developed countries.

74 rease in autoimmune and allergic diseases in developed countries.

75 n the rapidly increasing rates of obesity in developed countries.

76 iratory disease are major causes of death in developed countries.

77 e increase concentrated in the world's least developed countries.

78 colitis constitute a major health problem in developed countries.

79 are problem worldwide both in developing and developed countries.

80 the most frequently diagnosed male cancer in developed countries.

81 n patients failing antiretroviral therapy in developed countries.

82 ining vaccine (RCV) was limited primarily to developed countries.

83 nsible for about one in a thousand deaths in developed countries.

84 e rates in Hai were similar to those seen in developed countries.

85 pears to be lower than that quoted for other developed countries.

86 ion (AMD) is a leading cause of blindness in developed countries.

87 s that affect the HIV-infected population in developed countries.

88 drome has become a leading health concern in developed countries.

89 ncer is a major cause of mortality in men in developed countries.

90 disease (CAD), the leading cause of death in developed countries.

91 Most research was done in developed countries.

92 f the primary preventable causes of death in developed countries.

93 cancer is the most common cancer in women in developed countries.

94 a and other emerging markets to consumers in developed countries.

95 rders and is a significant health problem in developed countries.

96 alignancy that is increasing in incidence in developed countries.

97 fection into a survivable chronic disease in developed countries.

98 eading cause of vaccine-preventable death in developed countries.

99 etofore the evidence for this was limited to developed countries.

100 lignancy of the genital tract among women in developed countries.

101 e, similar to what is seen in humans in less developed countries.

102 butes enormously to the burden of disease in developed countries.

103 fecting about one-third of the population in developed countries.

104 in low resource settings, especially in less developed countries.

105 use of acquired heart disease in children in developed countries.

106 the leading cause of infectious blindness in developed countries.

107 r and its precursors are highly prevalent in developed countries.

108 ERD) is prevalent worldwide, particularly in developed countries.

109 (HPV) vaccines have been introduced in most developed countries.

110 the SAGE, but the evidence was largely from developed countries.

111 correctable vision loss among the elderly in developed countries.

112 ma (HCC) incidence is rising rapidly in many developed countries.

113 leading cause of pediatric heart disease in developed countries.

114 ern countries, and access is limited in less developed countries.

115 together remain a leading cause of death in developed countries.

116 s a leading cause of death among newborns in developed countries.

117 ble illness and death in both developing and developed countries.

118 emain substantially higher than are those in developed countries.

119 dity and mortality of sickle-cell disease in developed countries.

120 patients with ESRD attributed to diabetes in developed countries.

121 est tests for meningitis and encephalitis in developed countries.

122 ncer (PCA) is a serious health issue in most developed countries.

123 Obesity is a growing epidemic in developed countries.

124 mong generic oncology drugs were reported in developed countries.

125 he leading source of infectious blindness in developed countries.

126 the most common hematological malignancy in developed countries.

127 sible visual impairment and blindness in the developed countries.

128 the rapid increase in the incidence of AD in developed countries.

129 oportion of adenocarcinomas, particularly in developed countries.

130 ons also occur in infants and the elderly in developed countries.

131 in low resource settings, especially in less developed countries.

132 s in Chinese adults were much higher than in developed countries.

133 reast cancers has increased steadily in most developed countries.

134 utions to the so-called cancer-cost curve in developed countries?

135 in low-mortality developing (19%, 16-22) and developed countries (20%, 17-22) compared with high-mort

136 substantially in children and adolescents in developed countries; 23.8% (22.9-24.7) of boys and 22.6%

137 ficantly higher in developing countries than developed countries (49.5% vs 12.5%).

138 l episodes occur worldwide each year, and in developed countries a considerable part of them are caus

139 e interval [CI], 0-2%) of all stillbirths in developed countries and 4% (95% CI, 2%-6%) in Africa wer

140 gic asthma are significant health burdens in developed countries and are increasing in prevalence.

141 creased during 1983 to 2002 predominantly in developed countries and at younger ages.

142 Rates are higher than those of other developed countries and have stagnated over the past dec

143 is increasingly prevalent in developing and developed countries and is associated with severe morbid

144 ed to only about 60% of eligible patients in developed countries and is negligible elsewhere.

145 Nepal is one of the world's least developed countries and is ranked 157 of 186 in the 2013

146 he leading causes of enteric disease in many developed countries and is the leading cause of enteric

147 majority of liver pathology in industrially developed countries and lack specific therapy.

148 takes are common in HIV-infected patients in developed countries and may affect the progression of at

149 transitions (FT) have been observed in many developed countries and more recently in the developing

150 English language published after 1990, from developed countries and of qualitative, quantitative or

151 mon non-skin cancer diagnosed among males in developed countries and the second leading cause of canc

152 the prevalence of end-stage renal disease in developed countries and the shortage of deceased donors

153 rising incidence of this cancer in low-risk developed countries and the strong public health interes

154 mplexity of VL is preventing scale-up beyond developed countries and there is a lack of awareness amo

155 f irreversible visual loss in the elderly in developed countries and typically affects more than 10%

156 ence in cases to controls could be high in a developed country and close to or even less than 1 in a

157 Obesity is on the rise in all developed countries, and a large part of this epidemic h

158 Life expectancy is increasing in most developed countries, and elderly people have the highest

159 is the most common gynaecological tumour in developed countries, and its incidence is increasing.

160 Its prevalence is high, especially among developed countries, and mainly reflects overnutrition a

161 herefore urgently needed, especially in less developed countries, and management of hypertension must

162 (T2D) affect the first world as well as less-developed countries, and now affect children as well.

163 more for some prescription drugs than other developed countries, and the high price and increasing c

164 one of the leading nosocomial infections in developed countries, and therapeutic choices are limited

165 otective factor in rural populations in less developed countries, and this appears to be the case whe

166 ases of hepatitis E viral (HEV) infection in developed countries are autochthonous.

167 , and the current low intakes in most modern developed countries are believed to contribute to a wide

168 with modern multidisciplinary treatments in developed countries are cured; however, of the approxima

169 suggest that many well-assessed fisheries in developed countries are moving toward sustainability.

170 lization and costs of end-of-life care among developed countries are of considerable policy interest.

171 and interventions that have improved care in developed countries are scarce.

172 es of infectious intestinal disease (IID) in developed countries are uncommon.

173 sease), whereas China more closely resembled developed countries (around 80% of DALYs attributable to

174 -like particles have been introduced in many developed countries as a primary prevention strategy.

175 d harms of universal iron supplementation in developed countries as evidenced by the recent conclusio

176 Abuse was equally reported in developing and developed countries as the reason for street involvement

177 e greater access to diagnostic facilities in developed countries as well as POC diagnostics in resour

178 ts was lowest among people born in the least developed countries, as indicated by GNI, where infectio

179 ted air pollution in both developed and less-developed countries, as well as the continued importance

180 In developed countries, bacterial contamination of platelet

181 ing cause of morbidity and mortality in more developed countries, being the 14th most common cause of

182 en observed in the past 2 decades, mainly in developed countries but also in developing regions.

183 and MRs of these conditions have improved in developed countries, but are increasing in developing co

184 work environment are increasingly common in developed countries, but few exist in developing countri

185 le impacts upon nutrition and food safety in developed countries, but further research is necessary t

186 revalence of peanut allergy has increased in developed countries, but little is known about developin

187 is the leading cause of infant mortality in developed countries, but the association between gestati

188 ntly increased during recent decades in some developed countries, but the impact of improved drug tre

189 e same direction as historically occurred in developed countries, but typically had a lower degree of

190 24.9 patients per million population and in developed countries by 21.8 per million population.

191 ping countries but significantly declined in developed countries by 5.3%.

192 an improve cardiovascular preventive care in developed countries by addressing risk factors including

193 Nearly all patients with retinoblastoma in developed countries can now be cured of their primary ca

194 in risk factor for the prevalent diseases of developed countries: cancer, cardiovascular disease and

195 The GPLN has not only developed country capacities, but it also serves as a mo

196 66 million DALYs), a number greater than all developed countries combined (50 million DALYs).

197 evidence-based nutrition recommendations in developed countries, concerted worldwide efforts and pol

198 ts conducted overwhelmingly under temperate, developed country conditions.

199 s-transmission takes place in developing and developed countries, contingent upon epidemiological pot

200 arable to those previously reported in other developed countries, CVD and mortality rates may not be

201 fferences between the INDs of developing and developed countries decline but remain large.

202 al disease dynamics: (i) the worried well in developed countries (demanding less risk while broadenin

203 equency of primary and secondary syphilis in developed countries, especially in young men.

204 Approximately 40% of US travelers to less developed countries experience diarrheal illness.

205 Particularly in developed countries, fostering legions of sustainability

206 alth care-related HCV outbreaks occurring in developed countries from 1990 to 2012 were collated, gro

207 host immunity and may protect people in less-developed countries from developing immunological diseas

208 hogenesis of AS has undergone transitions in developed countries, from rheumatic heart disease to a d

209 orts on fungal keratitis from developing and developed countries, fungal keratitis in Ethiopia is poo

210 In developed countries, G1P[8] strains constitute the major

211 score was 60 out of 100 (range 36-86), with developed countries generally performing better than dev

212 cause of irreversible severe vision loss in developed countries-given the suggestion that a healthy

213 Even in developed countries, half of glaucoma cases are undiagno

214 creasing incidence of whooping cough in many developed countries has been linked with waning immunity

215 inational antiretroviral therapies (cART) in developed countries has changed the course of Human Immu

216 Inadequate funding from developed countries has hampered international efforts t

217 Since 2006, the increase in adult obesity in developed countries has slowed down.

218 Less developed countries have a low incidence of immunologica

219 Donors in developed countries have a similar life expectancy and q

220 Developed countries have complex structures in place tha

221 ortant rotavirus vaccine (RotaTeq; Merck) in developed countries have demonstrated that it is well to

222 Immigrants to developed countries have low rates of aeroallergen sensi

223 In contrast to the United States and other developed countries, HCV transmission in developing coun

224 In developed countries, high rates of reversion following c

225 lder than 65 years who died with cancer in 7 developed countries in 2010, end-of-life care was more h

226 atic changes, with continuous improvement in developed countries in North America and Europe, but a c

227 evalence of allergic diseases has doubled in developed countries in the past several decades.

228 We explored trends in six developed countries in three types of indicators of chil

229 have been developed for protozoa endemic to developed countries, including Giardia lamblia (syn. G.

230 have been developed for protozoa endemic to developed countries, including Giardia lamblia and Crypt

231 Epidemiological evidence from developed countries indicates that Helicobacter pylori i

232 Most disease in developed countries is caused by serogroup B infection,

233 on cause of inflammatory cardiomyopathies in developed countries is lymphocytic myocarditis most comm

234 d to formulations currently on the market in developed countries is needed.

235 most common form of chronic liver disease in developed countries is nonalcoholic fatty liver disease

236 Most childhood meningitis in developed countries is now caused by viruses.

237 vival for childhood and adolescent cancer in developed countries is now in excess of 80% and the numb

238 ence of nosocomial infections in children in developed countries is still high, ranging from 8% to 30

239 onic obstructive pulmonary disease (COPD) in developed countries is uncertain.

240 st common cause of acquired heart disease in developed countries, is a self-limited vasculitis that i

241 th, the major cause of neonatal mortality in developed countries, is associated with intrauterine inf

242 evalent and increasingly common condition in developed countries, is associated with significantly lo

243 of the most frequent causes of blindness in developed countries, is strongly associated with aging.

244 As a Least Developed Country (LDC), adverse effects of climate chan

245 The least-developed countries, Nicaragua and Guatemala, experience

246 ermatitis (AD), and up to 20% of children in developed countries now suffer of the disease.

247 Zinc is a commonly overlooked deficiency in developed countries, occurring in infants, children, and

248 Phosphorus is abundant in the food supply of developed countries, occurring naturally in protein-rich

249 orldwide, and infection of children in under-developed countries often leads to high mortality rates.

250 rforms poorly relative to other economically developed countries on numerous indicators of care quali

251 ecords, nowadays routinely collected in many developed countries, open a new avenue for medical knowl

252 In contrast, the most developed countries, Panama and Costa Rica, had net wood

253 In developed countries, patients' CD4 cell counts at first

254 sm." We demonstrate that in some of the more developed countries, per capita metal use is more than 1

255 y bowel disease (IBD) are infrequent in less developed countries, possibly because helminths provide

256 By contrast with cancer prevalence in developed countries, prostate, lung, and cervical cancer

257 In developed countries, public health systems have become a

258 disease, the most prevalent liver disease in developed countries, remains difficult to manage with no

259 In developed countries, remarkable advances in antiretrovir

260 nsiderable impacts are possible in the least-developed countries, six of which could double or offset

261 , because susceptibility data originate from developed countries, studies in resource-poor settings u

262 sease is increasingly recognized in recently developed countries, such as India, mainly in patients w

263 ographically and demographically and that in developed countries, such as the US, SV40 prevalence rat

264 The more developed countries tend to have a substantial and incre

265 ore recent droughts and 8-11% more damage in developed countries than in developing ones.

266 m to capitalism, and an even wider sample of developed countries than previously studied.

267 dies with concurrent controls conducted in a developed country that evaluated a primary care-relevant

268 ing in the world (especially in emergent and developed countries), the development of a simple protoc

269 into a sporadic subtype that is diagnosed in developed countries, the Epstein-Barr-virus-associated e

270 In developed countries, the majority of all violent crime i

271 In developed countries, the majority of HCV infections are

272 not responding to treatment has declined in developed countries, the prevalence of TDR mutations has

273 nical registries has been well recognized in developed countries, their use for measuring the quality

274 read human exposure in the United States and developed countries, there are limited epidemiological s

275 aam were higher than seen in most studies in developed countries; this could be because of a differen

276 he most part, dependency criteria are met in developed countries through balanced diets, this is not

277 ewly presenting to care for HIV infection in developed countries to generate an estimate of the time

278 nd export of agricultural products away from developed countries toward Africa and Latin America.

279 In developed countries, treatment of thalassemia is also st

280 In developed countries, viral infections commonly cause myo

281 lent pneumococcal conjugate vaccine (PCV) in developed countries was enhanced by indirect protection

282 We found that mean BMI (kg/m(2)) in less-developed countries was generally higher within urban ar

283 vaccine candidates against GBS serotypes of developed countries, we also found their role in the att

284 Based on evidence from developed countries, we assumed that per capita in-use s

285 1,763 birth cohorts from 1800 to 1935 in 13 developed countries, we show that what is now seen as no

286 ascular disease risk prediction in people in developed countries when additional information is avail

287 Alcohol use disorders are common in developed countries, where alcohol is cheap, readily ava

288 es but accounts for less than 5% of cases in developed countries, where idiopathic, presumed viral ca

289 This would suggest that immigrants from less developed countries, where infections are more common, t

290 where infections are more common, to highly developed countries will have lower risk of asthma compa

291 g the next 5-10 years, blood availability in developed countries will need to increase again to meet

292 The present economic situation in many developed countries will place increased pressure on con

293 sion of circumcision in the health policy of developed countries will require further investigation.

294 ngs and deaths in both developing as well as developed countries with a substantial economic loss.

295 r pediatric cancer diagnosed in economically developed countries with B-cell precursor (BCP)-ALL, acc

296 he "Global North" (the group of economically developed countries with high per capita gross domestic

297 g the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, a

298 now the most common form of liver disease in developed countries, with an estimated prevalence of 20%

299 fastest-growing segment in the population in developed countries, with more than 30 million new cases

300 In developed countries, work-related asthma is the commones